Research programme: TL1A inhibitors - Absci
Alternative Names: ABS-101 - AbsciLatest Information Update: 09 Aug 2024
Price :
$50 *
At a glance
- Originator AbSci
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 08 Aug 2024 Absci plans a phase I trial for Inflammatory bowel diseases (Parenteral) in early 2025
- 31 Mar 2024 Pharmacokinetics and pharmacodynamics data from preclinical trial in Inflammatory bowel diseases released by Absci
- 29 Feb 2024 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral)